Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

D J Storey, M Sakala, C M McLean, H A Phillips, L K Dawson, L R Wall, M T Fallon, S Clive

Research output: Contribution to journalArticlepeer-review

Abstract

There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m(2), day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m(2), day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx.
Original languageEnglish
Pages (from-to)1657-1661
Number of pages5
JournalAnnals of Oncology
Volume21
Issue number8
DOIs
Publication statusPublished - 2010

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Deoxycytidine
  • Fluorouracil
  • Humans
  • Incidence
  • Middle Aged
  • Organoplatinum Compounds
  • Peripheral Nervous System Diseases
  • Retrospective Studies
  • Scotland

Fingerprint

Dive into the research topics of 'Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?'. Together they form a unique fingerprint.

Cite this